Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Autoimmune hepatitis can recur or appear de novo after liver transplantation, and it can result in hepatic fibrosis, graft loss, and re-transplantation. The goals of this review are to describe the prevalence, manifestations, putative pathogenic mechanisms, outcomes, and management of these occurrences. Autoimmune hepatitis recurs in 8–12 % of transplanted patients at 1 year and 36–68 % at 5 years. Recurrence may be asymptomatic and detected only by surveillance liver test abnormalities or protocol liver tissue examination. Autoantibodies that characterized the original disease, hypergammaglobulinemia, increased serum immunoglobulin G level, and histological findings of interface hepatitis, lymphoplasmacytic infiltration, perivenular hepatocyte necrosis, pseudo-rosetting, and acidophil bodies typify recurrence. Premature corticosteroid withdrawal and pre-transplant severity of the original disease are possible risk factors. De novo autoimmune hepatitis occurs in 1–7 % of patients 0.1–9 years after transplantation, especially in children. The appearance of autoantibodies may herald its emergence, and antibodies to glutathione-S-transferase T1 have been predictive of the disease. Recurrent disease may reflect recruitment of residual memory T lymphocytes and host-specific genetic predispositions, whereas de novo disease may reflect an allo-antigenic immune response and molecular mimicries that override self-tolerance. Treatment should be appropriate for autoimmune hepatitis and not based on anti-rejection drugs. Corticosteroid therapy alone or combined with azathioprine is the essential treatment. The substitution of mycophenolate mofetil for azathioprine and switch of the calcineurin inhibitor or its replacement with rapamycin have also been used for refractory disease. Re-transplantation has been necessary in 8–23 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.

    Article  PubMed  CAS  Google Scholar 

  2. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2007;53:43–78.

    PubMed  CAS  Google Scholar 

  3. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.

    Article  PubMed  CAS  Google Scholar 

  4. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13:701–706.

    Article  PubMed  CAS  Google Scholar 

  5. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028–2035.

    Article  PubMed  CAS  Google Scholar 

  6. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317–323.

    Article  PubMed  CAS  Google Scholar 

  7. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31:49–53.

    Article  PubMed  CAS  Google Scholar 

  8. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227–235.

    Article  PubMed  CAS  Google Scholar 

  9. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.

    Article  PubMed  CAS  Google Scholar 

  10. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851–856.

    Article  PubMed  CAS  Google Scholar 

  11. Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645–652.

    Article  PubMed  CAS  Google Scholar 

  12. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225–232.

    PubMed  CAS  Google Scholar 

  13. Gregorio GV, Choudhuri K, Ma Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol. 2003;133:404–413.

    Article  PubMed  CAS  Google Scholar 

  14. Bogdanos DP, Lenzi M, Okamoto M, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol. 2004;17:83–92.

    PubMed  CAS  Google Scholar 

  15. Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol Immunol. 2004;40:1113–1120.

    Article  PubMed  CAS  Google Scholar 

  16. Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology. 2008;48:1013–1015.

    Article  PubMed  Google Scholar 

  17. Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol. 1998;161:3527–3535.

    PubMed  CAS  Google Scholar 

  18. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 2002;8:505–513.

    Article  PubMed  Google Scholar 

  19. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl Surg. 1995;1:109–115.

    PubMed  CAS  Google Scholar 

  20. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl. 2001;7:285–291.

    Article  PubMed  CAS  Google Scholar 

  21. Kerkar N, Hadzic N, Davies ET, et al. De novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409–413.

    Article  PubMed  CAS  Google Scholar 

  22. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313–333.

    PubMed  CAS  Google Scholar 

  23. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315–330.

    Article  PubMed  Google Scholar 

  24. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689–700.

    Article  PubMed  Google Scholar 

  25. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871.

    Article  PubMed  CAS  Google Scholar 

  26. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631.

    Article  PubMed  Google Scholar 

  27. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374–1380.

    Article  PubMed  CAS  Google Scholar 

  28. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302–308.

    Article  PubMed  Google Scholar 

  29. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–538.

    Article  PubMed  Google Scholar 

  30. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314–2328.

    Article  PubMed  CAS  Google Scholar 

  31. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360–365.

    Article  PubMed  CAS  Google Scholar 

  32. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34:659–665.

    Article  PubMed  CAS  Google Scholar 

  33. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 2004;24:322–329.

    Article  PubMed  Google Scholar 

  34. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263–270.

    Article  PubMed  Google Scholar 

  35. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol. 2004;28:471–478.

    Article  PubMed  Google Scholar 

  36. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–249.

    Article  PubMed  CAS  Google Scholar 

  37. Sempoux C, Horsmans Y, Lerut J, Rahier J, Geubel A. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver. 1997;17:311–315.

    Article  PubMed  CAS  Google Scholar 

  38. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001;7:302–310.

    Article  PubMed  CAS  Google Scholar 

  39. Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation. Ann Gastroenterol Hepatol. 2010;1:79–89.

    Google Scholar 

  40. Jones DE, James OF, Portmann B, et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology. 1999;30:53–57.

    Article  PubMed  CAS  Google Scholar 

  41. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology. 2001;34:464–470.

    Article  PubMed  CAS  Google Scholar 

  42. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation. 2001;71:664–668.

    Article  PubMed  CAS  Google Scholar 

  43. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006;44:489–501.

    Article  PubMed  Google Scholar 

  44. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl. 2008;14:750–755.

    Article  PubMed  Google Scholar 

  45. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 2008;14:861–871.

    Article  PubMed  Google Scholar 

  46. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl. 2008;14:625–632.

    Article  PubMed  Google Scholar 

  47. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008;14:1281–1286.

    Article  PubMed  Google Scholar 

  48. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation. 1984;37:363–365.

    Article  PubMed  CAS  Google Scholar 

  49. Wright HL, Bou-Abboud CF, Hassanein T, et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation. 1992;53:136–139.

    Article  PubMed  CAS  Google Scholar 

  50. Birnbaum AH, Benkov KJ, Pittman NS, et al. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr. 1997;25:20–25.

    PubMed  CAS  Google Scholar 

  51. Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation. 1998;66:1645–1650.

    Article  PubMed  CAS  Google Scholar 

  52. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68:253–256.

    Article  PubMed  CAS  Google Scholar 

  53. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30:131–141.

    Article  PubMed  CAS  Google Scholar 

  54. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002;8:519–526.

    Article  PubMed  Google Scholar 

  55. Yusoff IF, House AK, De Boer WB, et al. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol. 2002;17:203–207.

    Article  PubMed  Google Scholar 

  56. Duclos-Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut. 2003;52:893–897.

    Article  PubMed  Google Scholar 

  57. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transpl. 2004;18:62–69.

    Article  Google Scholar 

  58. Duclos-Vallee JC. Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation. Acta Gastroenterol Belg. 2005;68:331–336.

    PubMed  Google Scholar 

  59. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813–1824.

    Article  PubMed  Google Scholar 

  60. Montano-Loza AJ, Mason AL, Ma M, et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15:1254–1261.

    Article  PubMed  Google Scholar 

  61. Yao H, Michitaka K, Tokumoto Y, et al. Recurrence of autoimmune hepatitis after liver transplantation without elevation of alanine aminotransferase. World J Gastroenterol. 2007;13:1618–1621.

    PubMed  Google Scholar 

  62. Hytiroglou P, Gutierrez JA, Freni M, et al. Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: a blind histologic study. Hepatol Res. 2009;39:577–584.

    Article  PubMed  Google Scholar 

  63. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology. 2000;32:185–192.

    Article  PubMed  CAS  Google Scholar 

  64. Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg. 1999;5:375–380.

    Article  PubMed  CAS  Google Scholar 

  65. Junge G, Neuhaus R, Schewior L, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc. 2005;37:1695–1696.

    Article  PubMed  CAS  Google Scholar 

  66. Hayashi M, Keeffe EB, Krams SM, et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg. 1998;4:208–214.

    Article  PubMed  CAS  Google Scholar 

  67. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis. 2002;22:379–386.

    Article  PubMed  Google Scholar 

  68. Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin Liver Dis. 2000;20:481–495.

    Article  PubMed  CAS  Google Scholar 

  69. Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl. 2009;15:931–938.

    Article  PubMed  Google Scholar 

  70. Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol. 2009;3:257–268.

    Article  PubMed  Google Scholar 

  71. Rosenthal P, Emond JC, Heyman MB, et al. Pathological changes in yearly protocol liver biopsy specimens from healthy pediatric liver recipients. Liver Transpl Surg. 1997;3:559–562.

    Article  PubMed  CAS  Google Scholar 

  72. Mells G, Neuberger J. Protocol liver allograft biopsies. Transplantation. 2008;85:1686–1692.

    Article  PubMed  Google Scholar 

  73. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl. 2001;7:790–796.

    Article  PubMed  CAS  Google Scholar 

  74. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.

    Article  PubMed  CAS  Google Scholar 

  75. Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.

    Article  PubMed  CAS  Google Scholar 

  76. Duclos-Vallee JC, Yilmaz F, Johanet C, et al. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transpl. 2005;19:591–599.

    Article  Google Scholar 

  77. Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421–3438.

    Article  PubMed  Google Scholar 

  78. O’Grady JG. Phenotypic expression of recurrent disease after liver transplantation. Am J Transpl. 2010;10:1149–1154.

    Article  Google Scholar 

  79. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation. 2001;72:267–272.

    Article  PubMed  CAS  Google Scholar 

  80. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992;103:1290–1295.

    PubMed  CAS  Google Scholar 

  81. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol. 2000;33:163–166.

    Article  PubMed  CAS  Google Scholar 

  82. Lohse AW, Obermayer-Straub P, Gerken G, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease—possible association with a steroid-resistant transplant rejection episode. J Hepatol. 1999;31:149–155.

    Article  PubMed  CAS  Google Scholar 

  83. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology. 1993;18:998–1005.

    Article  PubMed  CAS  Google Scholar 

  84. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.

    Article  PubMed  Google Scholar 

  85. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–1548.

    Article  PubMed  Google Scholar 

  86. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50:538–545.

    Article  PubMed  Google Scholar 

  87. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997;63:243–249.

    Article  PubMed  CAS  Google Scholar 

  88. Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid-dependent after liver transplantation? Liver Transpl Surg. 1999;5:460–463.

    Article  PubMed  CAS  Google Scholar 

  89. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transpl Proc. 2007;39:1166–1170.

    Article  CAS  Google Scholar 

  90. Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation: a disease continuum or a fresh start? Liver Transpl. 2009;15:1169–1171.

    Article  PubMed  Google Scholar 

  91. Nunez-Martinez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transpl Proc. 2003;35:1857–1858.

    Article  CAS  Google Scholar 

  92. Hess AD, Fischer AC. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation. 1989;48:895–900.

    Article  PubMed  CAS  Google Scholar 

  93. Hess AD, Fischer AC, Horwitz LR, Laulis MK. Cyclosporine-induced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression. Transpl Proc. 1993;25:2811–2813.

    CAS  Google Scholar 

  94. Hess AD, Horwitz LR, Laulis MK. Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo. Transpl Proc. 1993;25:1218–1221.

    CAS  Google Scholar 

  95. Hess AD, Horwitz LR, Laulis MK, Fuchs E. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol. 1993;69:341–350.

    Article  PubMed  CAS  Google Scholar 

  96. Gotz G, Neuhaus R, Bechstein WO, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transpl Proc. 1999;31:430–431.

    Article  CAS  Google Scholar 

  97. Cooper MH, Hartman GG, Starzl TE, Fung JJ. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. Transpl Proc. 1991;23:3234–3235.

    CAS  Google Scholar 

  98. Hess DA, O’Leary EF, Lee JT, et al. Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole. FASEB J. 2001;15:1855–1857.

    PubMed  CAS  Google Scholar 

  99. Beschorner WE, Suresch DL, Shinozawa T, Santos GW, Hess AD. Thymic immunopathology after cyclosporine: effect of irradiation and age on medullary involution and recovery. Transpl Proc. 1988;20:1072–1078.

    CAS  Google Scholar 

  100. Lotem J, Kama R, Sachs L. Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin. Proc Natl Acad Sci USA. 1999;96:12016–12020.

    Article  PubMed  CAS  Google Scholar 

  101. Wang HG, Pathan N, Ethell IM, et al. Ca2 + -induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339–343.

    Article  PubMed  CAS  Google Scholar 

  102. Bucy RP, Xu XY, Li J, Huang G. Cyclosporin A-induced autoimmune disease in mice. J Immunol. 1993;151:1039–1050.

    PubMed  CAS  Google Scholar 

  103. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med. 1983;158:1–8.

    Article  PubMed  CAS  Google Scholar 

  104. Ahmed M, Mutimer D, Hathaway M, et al. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transpl Proc. 1997;29:496.

    Article  CAS  Google Scholar 

  105. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology. 2000;32:693–700.

    Article  PubMed  CAS  Google Scholar 

  106. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250–259.

    Article  PubMed  CAS  Google Scholar 

  107. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215–221.

    Article  PubMed  CAS  Google Scholar 

  108. Devlin J, Donaldson P, Portmann B, et al. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg. 1995;1:162–165.

    Article  PubMed  CAS  Google Scholar 

  109. Neumann UP, Guckelberger O, Langrehr JM, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation. 2003;75:132–137.

    Article  PubMed  CAS  Google Scholar 

  110. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol. 2003;170:1481–1489.

    PubMed  CAS  Google Scholar 

  111. Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the ‘glass of molecular mimicry’ half full or half empty? J Autoimmun. 2010;34:38–44.

    Article  PubMed  CAS  Google Scholar 

  112. Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183–1187.

    Article  PubMed  CAS  Google Scholar 

  113. Huppertz HI, Treichel U, Gassel AM, Jeschke R. Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204–208.

    Article  PubMed  CAS  Google Scholar 

  114. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409–1422.

    Article  PubMed  CAS  Google Scholar 

  115. Christen U, Holdener M, Hintermann E. Cytochrome P450 2D6 as a model antigen. Dig Dis. 2010;28:80–85.

    Article  PubMed  Google Scholar 

  116. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370–1378.

    Article  PubMed  CAS  Google Scholar 

  117. Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science. 1998;279:1344–1347.

    Article  PubMed  CAS  Google Scholar 

  118. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci. 2002;47:2139–2150.

    Article  PubMed  CAS  Google Scholar 

  119. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology. 1992;103:1041–1047.

    PubMed  CAS  Google Scholar 

  120. Yoshizawa K, Ota M, Katsuyama Y, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol. 2005;42:578–584.

    Article  PubMed  CAS  Google Scholar 

  121. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol. 2003;18:63–67.

    Article  PubMed  CAS  Google Scholar 

  122. Vazquez-Garcia MN, Alaez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol. 1998;28:985–990.

    Article  PubMed  CAS  Google Scholar 

  123. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146–150.

    Article  PubMed  CAS  Google Scholar 

  124. Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906–1913.

    Article  PubMed  CAS  Google Scholar 

  125. Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol. 2001;62:165–169.

    Article  PubMed  CAS  Google Scholar 

  126. Djilali-Saiah I, Fakhfakh A, Louafi H, et al. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol. 2006;45:844–850.

    Article  PubMed  CAS  Google Scholar 

  127. Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322–1329.

    Article  PubMed  CAS  Google Scholar 

  128. Fan LY, Tu XQ, Zhu Y, et al. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol. 2005;11:2768–2772.

    PubMed  CAS  Google Scholar 

  129. Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005;20:249–255.

    Article  PubMed  CAS  Google Scholar 

  130. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126–131.

    Article  PubMed  CAS  Google Scholar 

  131. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26:1054–1066.

    Article  PubMed  CAS  Google Scholar 

  132. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643–649.

    Article  PubMed  CAS  Google Scholar 

  133. Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology. 2001;34:494–501.

    Article  PubMed  CAS  Google Scholar 

  134. Renous R, Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. Characterization of the antigenicity of the formiminotransferase-cyclodeaminase in type 2 autoimmune hepatitis. Exp Cell Res. 2004;292:332–341.

    Article  PubMed  CAS  Google Scholar 

  135. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol. 1984;55:347–354.

    PubMed  CAS  Google Scholar 

  136. Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis. 1991;11:215–222.

    Article  PubMed  CAS  Google Scholar 

  137. Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364–374.

    Article  PubMed  CAS  Google Scholar 

  138. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59–65.

    Article  PubMed  CAS  Google Scholar 

  139. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg. 1999;5:S1–S20.

    Article  PubMed  CAS  Google Scholar 

  140. Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature. 1988;336:70–73.

    Article  PubMed  CAS  Google Scholar 

  141. Sprent J. Lifespans of naive, memory and effector lymphocytes. Curr Opin Immunol. 1993;5:433–438.

    Article  PubMed  CAS  Google Scholar 

  142. McLean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA. 1995;92:3707–3711.

    Article  PubMed  CAS  Google Scholar 

  143. Umeki S, Kusunoki Y, Cologne JB, et al. Lifespan of human memory T-cells in the absence of T-cell receptor expression. Immunol Lett. 1998;62:99–104.

    Article  PubMed  CAS  Google Scholar 

  144. Obhrai JS, Oberbarnscheidt MH, Hand TW, et al. Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs. J Immunol. 2006;176:4051–4058.

    PubMed  CAS  Google Scholar 

  145. Bell EB, Westermann J. CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol. 2008;29:405–411.

    Article  PubMed  CAS  Google Scholar 

  146. Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl. 2004;10:1166–1172.

    Article  PubMed  Google Scholar 

  147. Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 2010;55:1761–1769.

    Article  PubMed  CAS  Google Scholar 

  148. Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Liver Transpl. 2001;7:S99–S108.

    Article  PubMed  CAS  Google Scholar 

  149. Rowe IA, Webb K, Gunson BK, et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21:459–465.

    Article  PubMed  Google Scholar 

  150. Cattan P, Berney T, Conti F, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int. 2002;15:34–38.

    Article  PubMed  Google Scholar 

  151. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269–291.

    Article  PubMed  CAS  Google Scholar 

  152. Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol. 2012;10:346–353.

    Article  PubMed  Google Scholar 

  153. Czaja AJ, Wang KK, Shiels MT, Katzmann JA. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol. 1993;17:180–186.

    Article  PubMed  CAS  Google Scholar 

  154. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10:81–90; discussion 91–82.

    Google Scholar 

  155. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol. 2000;109:16–22.

    Article  PubMed  Google Scholar 

  156. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol. 2001;2:78–82.

    Google Scholar 

  157. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Design. 2011;17:3120–3140.

    Article  CAS  Google Scholar 

  158. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890–897.

    Article  PubMed  CAS  Google Scholar 

  159. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685–689.

    Article  PubMed  CAS  Google Scholar 

  160. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29:286–296.

    Article  PubMed  Google Scholar 

  161. Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int. 2009;22:144–152.

    Article  PubMed  Google Scholar 

  162. Rumbo C, Shneider BL, Emre SH. Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. Pediatr Transpl. 2004;8:571–575.

    Article  CAS  Google Scholar 

  163. Hurtova M, Duclos-Vallee JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 2001;7:556–558.

    Article  PubMed  CAS  Google Scholar 

  164. Hasenbein W, Albani J, Englert C, et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transpl. 2006;10:938–942.

    Article  CAS  Google Scholar 

  165. Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. Dig Dis Sci. 1990;35:693–697.

    Article  PubMed  CAS  Google Scholar 

  166. Kowdley KV, Keeffe EB. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am. 1995;24:991–1001.

    PubMed  CAS  Google Scholar 

  167. Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int (Off J Eur Soc Organ Transpl). 2000;13:73–78.

    CAS  Google Scholar 

  168. Taniai N, Akimaru K, Ishikawa Y, et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nihon Med Sch. 2008;75:187–191.

    Article  PubMed  Google Scholar 

  169. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.

    Article  PubMed  CAS  Google Scholar 

  170. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723–727.

    Article  PubMed  CAS  Google Scholar 

  171. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799–802.

    Article  PubMed  CAS  Google Scholar 

  172. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:1036–1040.

    Article  PubMed  CAS  Google Scholar 

  173. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54:2519–2522.

    Article  PubMed  CAS  Google Scholar 

  174. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588–592.

    PubMed  Google Scholar 

  175. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321–326.

    PubMed  Google Scholar 

  176. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819–825.

    Article  PubMed  CAS  Google Scholar 

  177. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063–3070.

    Article  PubMed  CAS  Google Scholar 

  178. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009;51:156–160.

    Article  PubMed  CAS  Google Scholar 

  179. Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8–10.

    Article  PubMed  CAS  Google Scholar 

  180. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335–343.

    Article  PubMed  CAS  Google Scholar 

  181. Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol. 2011;5:517–522.

    Article  PubMed  CAS  Google Scholar 

  182. Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation. 2003;76:130–136.

    Article  PubMed  CAS  Google Scholar 

  183. Czaja AJ. Autoimmune hepatitis: focusing on therapies other than steroids. Can J Gastroenterol (accepted for publication).

  184. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transpl. 2005;5:1085–1089.

    Article  Google Scholar 

  185. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758.

    Article  PubMed  CAS  Google Scholar 

  186. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–1945.

    Article  PubMed  CAS  Google Scholar 

  187. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.

    Article  PubMed  CAS  Google Scholar 

  188. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation. 2006;81:445–454.

    Article  PubMed  CAS  Google Scholar 

  189. Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr. 2001;32:131–136.

    Article  PubMed  CAS  Google Scholar 

  190. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol. 2001;126:535–539.

    Article  PubMed  CAS  Google Scholar 

  191. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation. 2004;78:128–135.

    Article  PubMed  Google Scholar 

  192. Gibelli NE, Tannuri U, Mello ES, et al. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation. Pediatr Transpl. 2006;10:371–376.

    Article  Google Scholar 

  193. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transpl. 2007;7:955–963.

    Article  CAS  Google Scholar 

  194. Eguchi S, Takatsuki M, Hidaka M, et al. De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease. J Gastroenterol Hepatol. 2008;23:e165–e169.

    Article  PubMed  CAS  Google Scholar 

  195. Cho JM, Kim KM, Oh SH, et al. De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution’s experience. Transpl Proc. 2011;43:2394–2396.

    Article  CAS  Google Scholar 

  196. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43:1109–1117.

    Article  PubMed  Google Scholar 

  197. Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl. 2009;15:530–539.

    Article  PubMed  Google Scholar 

  198. Guido M, Burra P. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis. 2011;31:71–81.

    Article  PubMed  Google Scholar 

  199. Tan CK, Sian Ho JM. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transpl. 2001;7:461–465.

    Article  PubMed  CAS  Google Scholar 

  200. Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transpl Proc. 2006;38:1467–1470.

    Article  CAS  Google Scholar 

  201. Yoshizawa K, Shirakawa H, Ichijo T, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transpl. 2008;22:385–390.

    Article  Google Scholar 

  202. Zhang Y, Wang B, Wang T. De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis: a case report. Transpl Proc. 2010;42:3854–3857.

    Article  CAS  Google Scholar 

  203. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci. 2001;46:140–147.

    Article  PubMed  CAS  Google Scholar 

  204. McNally RJ, James PW, Ducker S, James OF. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology. 2011;54:2099–2103.

    Article  PubMed  Google Scholar 

  205. Richter A, Grabhorn E, Helmke K, et al. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transpl. 2007;21:427–432.

    Article  Google Scholar 

  206. Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.

    Article  PubMed  Google Scholar 

  207. Tamaro G, Sonzogni A, Torre G. Monitoring “de novo” autoimmune hepatitis (LKM positive) by serum type-IV collagen after liver transplant: a paediatric case. Clin Chim Acta. 2001;310:25–29.

    Article  PubMed  CAS  Google Scholar 

  208. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002;35:349–356.

    Article  PubMed  CAS  Google Scholar 

  209. Huguet S, Vinh J, Johanet C, et al. Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann NY Acad Sci. 2007;1109:345–357.

    Article  PubMed  CAS  Google Scholar 

  210. Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transpl Proc. 2005;37:3968–3969.

    Article  CAS  Google Scholar 

  211. Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr. 2007;45:222–227.

    Article  PubMed  CAS  Google Scholar 

  212. Aguilera I, Sousa JM, Praena JM, Gomez-Bravo MA, Nunez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transpl. 2011;25:207–212.

    Article  CAS  Google Scholar 

  213. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224–1231.

    Article  PubMed  CAS  Google Scholar 

  214. Inui A, Sogo T, Komatsu H, Miyakawa H, Fujisawa T. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transpl. 2005;11:504–507.

    Article  PubMed  Google Scholar 

  215. Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children—what is different from adulthood? Best Pract Res Clin Gastroenterol. 2011;25:783–795.

    Article  PubMed  Google Scholar 

  216. Gibelli NE, Tannuri U, Pinho-Apezzato ML, et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transpl Proc. 2009;41:901–903.

    Article  CAS  Google Scholar 

  217. Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol. 1995;19:192–206.

    Article  PubMed  CAS  Google Scholar 

  218. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638–645.

    Article  PubMed  CAS  Google Scholar 

  219. Lefkowitch JH. Diagnostic issues in liver transplantation pathology. Clin Liver Dis. 2002;6:555–570.

    Google Scholar 

  220. Quiroga J, Colina I, Demetris AJ, Starzl TE, Van Thiel DH. Cause and timing of first allograft failure in orthotopic liver transplantation: a study of 177 consecutive patients. Hepatology. 1991;14:1054–1062.

    Article  PubMed  CAS  Google Scholar 

  221. Blakolmer K, Jain A, Ruppert K, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000;69:2330–2336.

    Article  PubMed  CAS  Google Scholar 

  222. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology. 1991;13:882–891.

    Article  PubMed  CAS  Google Scholar 

  223. Lowes JR, Hubscher SG, Neuberger JM. Chronic rejection of the liver allograft. Gastroenterol Clin North Am. 1993;22:401–420.

    PubMed  CAS  Google Scholar 

  224. Demetris AJ, Seaberg EC, Batts KP, et al. Chronic liver allograft rejection: a National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Am J Surg Pathol. 1998;22:28–39.

    Article  PubMed  CAS  Google Scholar 

  225. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792–799.

    Article  PubMed  CAS  Google Scholar 

  226. Backman L, Gibbs J, Levy M, et al. Causes of late graft loss after liver transplantation. Transplantation. 1993;55:1078–1082.

    Article  PubMed  CAS  Google Scholar 

  227. Tsamandas AC, Jain AB, Felekouras ES, et al. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997;64:252–257.

    Article  PubMed  CAS  Google Scholar 

  228. Herzog D, Soglio DB, Fournet JC, et al. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl. 2008;14:946–955.

    Article  PubMed  Google Scholar 

  229. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 2007;13:966–974.

    Article  PubMed  Google Scholar 

  230. Ludwig J, Gross JB Jr, Perkins JD, Moore SB. Persistent centrilobular necroses in hepatic allografts. Hum Pathol. 1990;21:656–661.

    Article  PubMed  CAS  Google Scholar 

  231. Khettry U, Backer A, Ayata G, et al. Centrilobular histopathologic changes in liver transplant biopsies. Hum Pathol. 2002;33:270–276.

    Article  PubMed  Google Scholar 

  232. Krasinskas AM, Ruchelli ED, Rand EB, Chittams JL, Furth EE. Central venulitis in pediatric liver allografts. Hepatology. 2001;33:1141–1147.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

This review did not receive financial support from a funding agency or institution, and Albert J. Czaja, MD has no conflict of interests to declare.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN, 55905, USA

    Albert J. Czaja

Authors
  1. Albert J. Czaja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert J. Czaja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czaja, A.J. Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation. Dig Dis Sci 57, 2248–2266 (2012). https://doi.org/10.1007/s10620-012-2179-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2179-3

Keywords

Search

Navigation